PRCT Form 4: Director Exercises 26,749 Options at $1.33

The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share.

Rhea-AI Filing Summary

The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.

Positive

• Director increased ownership by exercising 26,749 options, raising beneficial holdings to 35,152 shares.
• Options were fully vested and exercisable, and the exercise was completed as a cash transaction at $1.33 per share.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director exercised fully vested options to acquire 26,749 shares at $1.33, modestly increasing insider ownership.

The transaction is a routine insider option exercise rather than an open-market purchase or sale. A cash exercise of 26,749 options increases total reported beneficial ownership to 35,152 shares, with 14,363 shares held indirectly through a trust. For investors this is a limited, non-dilutive transfer from option to common stock that does not change company cash flow materially beyond the exercise proceeds.

Corporate Governance Expert

TL;DR: This Form 4 documents a standard, fully vested option exercise by a director; disclosure appears complete and timely.

The filing identifies the reporter as a director and indicates the option was fully vested and exercised for cash. Reporting was done on a single-person Form 4 and signed by an attorney-in-fact. No additional derivative holdings remain for the reporter post-transaction. From a governance and disclosure standpoint, the Form 4 provides the required details: dates, quantities, price, and ownership form.

Insider Trade Summary

26,749 shares exercised/converted

Exercise 3 txns

Insider Desai Antal Rohit

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	26,749	$0.00	$0.00
Exercise	Common Stock	26,749	$1.33	$36K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 35,152 shares (Direct); Common Stock — 14,363 shares (Indirect, By The 2:22 DNA Trust)

Footnotes (2)

1. F1. Transaction is a cash exercise by the reporting person.
2. F2. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PRCT director Antal Rohit Desai report on Form 4?

He reported a cash exercise of 26,749 stock options on 08/14/2025 at a price of $1.33 per share.

How many PRCT shares does Mr. Desai beneficially own after the transaction?

The Form 4 states he beneficially owns 35,152 shares following the reported transaction.

Does the filing disclose any indirect holdings for Mr. Desai?

Yes. The filing shows 14,363 shares are held indirectly through The 2:22 DNA Trust.

Was the option exercised by Mr. Desai vested at the time of exercise?

Yes. The filing explains the option was fully vested and exercisable at the time of the cash exercise.

Who signed the Form 4 filing for Mr. Desai?

The Form 4 was signed by Jonathan Stone, Attorney-in-Fact for Mr. Antal Rohit Desai on 08/15/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/15/2025 - 04:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Desai Antal Rohit

(Last) (First) (Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		M		26,749	A	$1.33	35,152	D
Common Stock								14,363	I	By The 2:22 DNA Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.33	08/14/2025		M(1)			26,749	(2)	09/17/2025	Common Stock	26,749	$0	0	D

Explanation of Responses:

1. Transaction is a cash exercise by the reporting person.

2. The option is fully vested and exercisable.

Remarks:

	/s/ Jonathan Stone, Attorney-in Fact for Mr. Antal Rohit Desai	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.